Glaxo Group Limited

Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property Development Limited

Steven Leslie Sollis

Alan D Borthwick

John Liddle

Paul Graham Wyatt

Deirdre Mary Bernadette Hickey

Andrew McMurtrie Mason

Anna Katrin Szardenings

Neil Derek Miller

David George Hubert Livermore

Fabrizio Nerozzi

Richard Jonathan Hatley

Diane Mary Coe

Panayiotis Alexandrou Procopiou

Anthony William James Cooper

Niall Andrew Anderson

John Martin Pritchard

Stefan Senger

Ashley Paul Hancock

David George Allen

David House

Matthew Howard James Campbell-Crawford

Paul Martin Gore

Sadie Vile

Seble Lemma

Caroline Wilson

The invention relates to compounds of Formula (I): wherein R, Rand Rare as defined in the description and claims, or pharmaceutically acceptable salts thereof, having &#x3b1;&#x3b2;integrin antagonist activity. The invention also relates to pharmaceutical compositions including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an &#x3b1;&#x3b2;integrin antagonist is indicated, in particular the treatment of idiopathic pulmonary fibrosis.

Naphthyridines as integrin antagonists

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

Substituted diketopiperazines as oxytocin antagonists

The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

N-pyrazolyl carboxamides as CRAC channel inhibitors

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a mammal in need thereof of an effective amount of a compound of the formula (I) and/or a physiologically acceptable derivative thereof, wherein the substituents have the meaning given in the description. Disclosed are also novel compounds of formula (I) and processes for their preparation.

Growing community of inventors

Stevenage, United Kingdom

Steven Leslie Sollis